Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2017

View Archived Issues

ProMIS Neurosciences selects third lead product for Alzheimer's disease

TLD-1633 demonstrates increased efficacy in glioblastoma multiforme cell line

Phase II results presented for tezepelumab in adults with uncontrolled asthma

First data on AZD-7594 in asthma patients disclosed

Daiichi Sankyo and MD Anderson enter AML research collaboration

Halozyme Therapeutics licenses its Enhanze drug-delivery technology to Roche

Collaborations Pharmaceuticals receives NIH award to repurpose drug for Chagas disease

Nemiralisib delivered via ELLIPTA device found to be safe and well tolerated

Harvard's Wyss Institute launches human Organ Chip project

Independent DMC recommends discontinuation of Prostvac phase III study in mCRPC

FDA approves Aliqopa for relapsed follicular lymphoma

Briviact monotherapy approved in U.S. for partial-onset seizures in adults

RDD Pharma wins grant to test RDD-0315 for fecal incontinence in SCI patients

Janssen files sNDA for Zytiga for earlier stages of metastatic prostate cancer

NovoBiotic Pharmaceuticals patents novel macrocyclic antibiotics

FDA expands indication for Sunovion's Aptiom

Bristol-Myers Squibb and Halozyme announce agreement to use Enhanze technology in immuno-oncology

Shenzhen Targetrx Biotechnology discloses IDO inhibitors

FDA grants expanded approval to Afluria Quadrivalent influenza vaccine

RET inhibitors disclosed in GlaxoSmithKline patent

EMA committee recommends approval of Trelegy Ellipta for COPD

Phase III PROSPER study in patients with nonmetastatic CRPC meets primary endpoint

Alios BioPharma presents FXR agonists for NASH

ALK-Abello reports data from phase III study of tree allergy SLIT tablets

Bayer Pharma divulges BRD4 inhibitors for cancer

FDA approves bevacizumab biosimilar Mvasi

Celgene studies CC-90010 in advanced solid tumors and relapsed or refractory NHL

MEDI-4166 shows safety in type 2 diabetes subjects

FDA approves Privigen to treat chronic inflammatory demyelinating polyneuropathy in adults

Da Volterra and Bioaster present beta-lactamase variants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Harbour Biomed closes busy year with $1B+ BMS deal
BioWorld
Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...